GOG 3016/ENGOT-cx9: An open-label, multi-national,...

Gynecologic Oncology 2020 / 10 Vol. 159

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer

Tewari, K.S., Monk, B.J., Oaknin, A., Lheureux, S., Zagouri, F., Rischin, D., Hasegawa, K., Kim, Y.M., Pereira, R., Sadozye, A., Wang, P.H., Lisyanskaya, A., Samouëlian, V., Kim, H.S., Zambrano, M.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
159
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2020.05.233
Date:
October, 2020
File:
PDF, 151 KB
2020
Conversion to is in progress
Conversion to is failed